Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GDC-0152 |
| Synonyms | |
| Therapy Description |
GDC-0152 is a SMAC mimetic compound, which antagonizes inhibitor of apoptosis proteins (IAPs), resulting in increased apoptosis and differentiation of tumor cells (PMID: 27490930, PMID: 31521127). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GDC-0152 | SMAC Mimetic 8 | GDC-0152 is a SMAC mimetic compound, which antagonizes inhibitor of apoptosis proteins (IAPs), resulting in increased apoptosis and differentiation of tumor cells (PMID: 27490930, PMID: 31521127). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN loss | glioblastoma | predicted - sensitive | GDC-0152 | Preclinical - Cell culture | Actionable | In a preclinical study, GDC-0152 treatment inhibited proliferation of PTEN-deficient glioblastoma cells in culture (PMID: 32737157). | 32737157 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|